Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

SITAGLIPTIN & METFORMIN

All products: general benefit

Other products in the same Health Canada class (A10B, A10BD) — coverage varies; not interchangeable

  • Dapagliflozin + metformin (Xigduo): general benefit
  • Empagliflozin + metformin (Synjardy): general benefit
  • Linagliptin + metformin (Jentadueto): general benefit
  • Metformin + saxagliptin (Komboglyze): general benefit
  • Canagliflozin (Invokana): general benefit
  • Dapagliflozin (Forxiga): general benefit

12 more in the class list below

Janumet · DIN 02333864 · 50mg & 850mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-08-13 — choose a marketed DIN from the same-category list.Discontinued 2025-08-13 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-08-13 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-08-13 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Janumet · DIN 02333864 Manufacturer: Merck Canada Inc.; listing date 2012-02-29 Health Canada: Cancelled post market since 2025-08-13 · brand JANUMET · ATC A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 850 MG · company Merck canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.4446 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81955 · Verify on the e-Formulary ↗ (DIN 02333864)

Source record
DIN 02333864: Janumet Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002038; group id 757; item number 1862; lccId None; manufacturer id MEK Source form: Tab; strength: 50mg & 850mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.7785; ministry $0.4446 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02333864 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81955 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin Malate/Metformin HCl · DIN 02509423 · $0.4446 Apo-Sitagliptin-Metformin · DIN 02435780 · $0.4446 Auro-Sitagliptin HCl and Metformin HCl · DIN 02547813 · $0.4446 Jamp Sitagliptin HCl / Metformin · DIN 02556197 · $0.4446 Reddy-Sitagliptin and Metformin HCl · DIN 02540126 · $0.4446 Sandoz Sitagliptin-Metformin · DIN 02503964 · $0.4446 Sitagliptin-Metformin · DIN 02529165 · $0.4446 Sitagliptin/Metformin · DIN 02560453 · $0.4446 Teva-Sitagliptin Malate / Metformin · DIN 02520508 · $0.4446
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2025-08-13 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered

Matched class: 68:20:02 Oral Anti-Diabetic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN Some products covered without a code (check the product listing): GLICLAZIDE, GLYBURIDE, METFORMIN HCL 68:20:02 Oral Anti-Diabetic Agents

DAPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab

EMPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 500mg, 5mg & 850mg, 12.5mg & 1000mg, 12.5mg & 500mg, 12.5mg & 850mg · Tab

LINAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

SAXAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

CANAGLIFLOZIN

· 8 products · General benefit · strengths: 100mg, 300mg · Tab

DAPAGLIFLOZIN

· 22 products · General benefit · strengths: 5mg, 10mg · Tab

EMPAGLIFLOZIN

· 2 products · General benefit · strengths: 10mg, 25mg · Tab

GLICLAZIDE

· 19 products · General benefit (18), Listed, not a benefit (1) · strengths: 60mg, 30mg, 80mg · ER Tab, SR Tab, Tab

GLYBURIDE

· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab

LINAGLIPTIN

· 1 products · General benefit · strengths: 5mg · Tab

METFORMIN HCL

· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab

SAXAGLIPTIN

· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:02 and 6 more
Full class listing Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS • JANUMET® (sitagliptin/metformin hydrochloride) and JANUMET® XR (sitagliptin/metformin hydrochloride extended-release) are indicated for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus inadequately controlled on metformin or in patients already being treated with the combination of sitagliptin and metformin. • Add-on combination: JANUMET® and JANUMET® XR are indicated for use as a triple combination therapy in adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with: o . sulfonylurea, o . premixed or long/intermediate acting insulin o . pioglitazone when the existing dual therapy with metformin, along with diet and exercise, does not provide adequate glycemic control (see 14 CLINICAL TRIALS). 1.1 Pediatrics • Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of JANUMET® and JANUMET® XR in pediatric patients… https://pdf.hres.ca/dpd_pm/00074655.PDF PM date: FEB 20, 2024 Source product: JANUMET; DIN 02333856; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.